Compare Pfizer Inc (PFE) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs TeraWulf Inc — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while TeraWulf Inc trades at $13.9 (market cap $7.19B). The key difference: Pfizer Inc is far larger — about 22.2× TeraWulf Inc's market cap, and Pfizer Inc pays a 6.14% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and TeraWulf Inc for 17 Days on average.
| PFE | WULF | |
|---|---|---|
Market Cap | $159.59B | $7.19B |
Volume | 30,937,010 | 27,440,950 |
Sector | Health | Financials |
52-Week High | $29.02 | $28.98 |
52-Week Low | $23.67 | $10.99 |
Typical Hold Time | 158 Days | 17 Days |
Enterprise Value | $211.09B | $9.80B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
WULF trades at $14.40, down 3.81% on the day, amid a volatile period for AI infrastructure stocks. The company shows strong analyst support with 14 buy ratings and a consensus price target of $34.92, but fundamentals reveal challenges: revenue of $168.46M in 2025 was overshadowed by a net loss of -$661.42M, resulting in negative profit margins. Recent news highlights the company's pivot to AI data center hosting, with UBS initiating bullish coverage citing constrained compute supply (UBS, September 23, 2026).
The outlook is bifurcated: analyst optimism contrasts with weak profitability and bearish technical signals. Investment opportunity lies in the AI hosting transition, but risks include persistent losses, high debt-to-asset ratio of 78.84%, and sector volatility. The stock's current price near key support at $14 suggests cautious sentiment despite long-term growth potential in AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
